Brisbane, Australia; Research Site:
A Study of MabThera (Rituximab) for Treatment of Mantle Cell Non-Hodgkin's Lymphoma After Bone Marrow or Blood Stem Cell Transplantation
Melbourne, Australia; Research Site:
A Study of MabThera (Rituximab) for Treatment of Mantle Cell Non-Hodgkin's Lymphoma After Bone Marrow or Blood Stem Cell Transplantation
Parkville, Australia; Research Site:
A Study of MabThera (Rituximab) for Treatment of Mantle Cell Non-Hodgkin's Lymphoma After Bone Marrow or Blood Stem Cell Transplantation
Perth, Australia; Research Site:
A Study of MabThera (Rituximab) for Treatment of Mantle Cell Non-Hodgkin's Lymphoma After Bone Marrow or Blood Stem Cell Transplantation
Sydney, Australia; Research Site:
A Study of MabThera (Rituximab) for Treatment of Mantle Cell Non-Hodgkin's Lymphoma After Bone Marrow or Blood Stem Cell Transplantation
Woolloongabba, Australia; Research Site:
A Study of MabThera (Rituximab) for Treatment of Mantle Cell Non-Hodgkin's Lymphoma After Bone Marrow or Blood Stem Cell Transplantation
Budapest, Hungary; Research Site:
A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma.
Debrecen, Hungary; Research Site:
A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma.
Gyor, Hungary; Research Site:
A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma.
Kaposvar, Hungary; Research Site:
A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma.
Miskolc, Hungary; Research Site:
A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma.
Pecs, Hungary; Research Site:
A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma.
Szeged, Hungary; Research Site:
A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma.
Zalaegerszeg, Hungary; Research Site:
A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma.
Bergamo, Italy; Research Site:
A Study of MabThera (Rituximab) Plus Sequential High-Dose Chemotherapy in Patients Newly Diagnosed With Mantle Cell Lymphoma
Bologna, Italy; Research Site:
A Study of MabThera (Rituximab) Plus Sequential High-Dose Chemotherapy in Patients Newly Diagnosed With Mantle Cell Lymphoma
Milano, Italy; Research Site:
A Study of MabThera (Rituximab) Plus Sequential High-Dose Chemotherapy in Patients Newly Diagnosed With Mantle Cell Lymphoma
Pavia, Italy; Research Site:
A Study of MabThera (Rituximab) Plus Sequential High-Dose Chemotherapy in Patients Newly Diagnosed With Mantle Cell Lymphoma
Roma, Italy; Research Site:
A Study of MabThera (Rituximab) Plus Sequential High-Dose Chemotherapy in Patients Newly Diagnosed With Mantle Cell Lymphoma
Torino, Italy; Research Site:
A Study of MabThera (Rituximab) Plus Sequential High-Dose Chemotherapy in Patients Newly Diagnosed With Mantle Cell Lymphoma
